Candidate VBI-2902 expressed a modified,‌ ‌prefusion‌ ‌form‌ ‌of‌ ‌the‌ ‌SARS-CoV-2‌ ‌spike‌ ‌protein‌ that ‌elicited‌ ‌a‌ ‌highly‌ ‌potent‌ ‌and‌ ‌focused‌ ‌neutralizing‌ ‌antibody‌ ‌response ‌and‌ ‌conferred‌ a ‌protective‌ ‌benefit‌ ‌in‌ ‌Syrian‌ ‌golden‌ ‌hamsters‌ that had ‌COVID-19. This was ‌assessed‌ ‌in‌ ‌terms‌ ‌of‌ ‌clinical‌ ‌disease‌, such as loss‌ ‌of‌ ‌body‌ ‌weight and‌ ‌lung‌ ‌inflammation. Also, the ‌vaccine‌ ‌candidate‌ ‌showed potential to be highly effective after a single dose, according to the data.

CEPI, VBI to develop COVID-19 vaccine against variants
The Coalition for Epidemic Preparedness Innovations (CEPI) will support the development of enveloped viruslike particle vaccine candidates against SARS-CoV-2...

FDA accepts VBI's hepatitis B vaccine BLA
The U.S. Food and Drug Administration (FDA) has accepted the biologics license application (BLA) submitted by VBI Vaccines for its 3-antigen prophylactic...

VBI provides COVID-19 vaccine updates amid supply chain delays
VBI Vaccines has provided preclinical updates on its two COVID-19 vaccine programs: VBI-2901, a trivalent pan-coronavirus vaccine candidate, and VBI-2902,...

VBI Vaccines move two COVID-19 vaccines to clinical trials
VBI Vaccines said that it has selected two of its COVID-19 vaccine candidates to proceed to a phase I/II clinical study expected to begin around the end...

Therapure to manufacture VBI coronavirus vaccines
Therapure Biomanufacturing has signed an agreement with VBI Vaccines for the manufacture of its coronavirus vaccine candidates.